Literature DB >> 16837503

Interstitial lung diseases associated with amyopathic dermatomyositis.

T Suda1, T Fujisawa, N Enomoto, Y Nakamura, N Inui, T Naito, D Hashimoto, J Sato, M Toyoshima, H Hashizume, K Chida.   

Abstract

The aim of the present study was to clarify the clinical characteristics and prognosis of patients with interstitial lung disease (ILD) associated with amyopathic dermatomyositis (ILD-ADM). The study consisted of 14 consecutive patients with ILD-ADM. Patients were classified into two categories, acute/subacute and chronic forms, according to the clinical presentation of ILD. The clinical features, responsiveness to therapy, and prognosis between the two forms were compared. Nine ILD-ADM patients were categorised as the acute/subacute form, and five as the chronic form. Arterial oxygen tension was significantly lower in the acute/subacute ILD than chronic ILD patients. On high-resolution computed tomography, ground-glass opacities were frequently found in the two forms, but consolidation was more common in acute/subacute ILD than chronic ILD. Bronchoalveolar lavage analysis showed higher numbers of total cells and lymphocytes in acute/subacute ILD than chronic ILD. Histologically, the most common finding was nonspecific interstitial pneumonia in the two forms, while diffuse alveolar damage was only found in acute/subacute ILD. Acute/subacute ILD was generally resistant to therapy, while chronic ILD responded well. Notably, the mortality of acute/subacute ILD was much higher than that of chronic ILD (67 versus 0%, respectively). In conclusion, interstitial lung disease associated with amyopathic dermatomyositis includes two different forms, the acute/subacute and chronic forms, with distinct prognoses.

Entities:  

Mesh:

Year:  2006        PMID: 16837503     DOI: 10.1183/09031936.06.00038806

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  35 in total

1.  Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.

Authors:  Lesley Ann Saketkoo; Dana P Ascherman; Vincent Cottin; Lisa Christopher-Stine; Sonye K Danoff; Chester V Oddis
Journal:  Curr Rheumatol Rev       Date:  2010-05

2.  Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations.

Authors:  Pamela A Morganroth; Mary Elizabeth Kreider; Joyce Okawa; Lynne Taylor; Victoria P Werth
Journal:  Arch Dermatol       Date:  2010-07

Review 3.  Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

Authors:  Tsuneyo Mimori; Ran Nakashima; Yuji Hosono
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

Review 4.  The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies.

Authors:  Ilaria Cavazzana; Micaela Fredi; Carlo Selmi; Angela Tincani; Franco Franceschini
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

5.  Interstitial lung disease in clinically amyopathic dermatomyositis (CADM) patients: a retrospective study of 41 Chinese Han patients.

Authors:  Yuechi Sun; Yuan Liu; Bing Yan; Guixiu Shi
Journal:  Rheumatol Int       Date:  2012-11-10       Impact factor: 2.631

6.  Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis.

Authors:  Yuzo Suzuki; Hiroshi Hayakawa; Seiichi Miwa; Masahiro Shirai; Masato Fujii; Hitoshi Gemma; Takafumi Suda; Kingo Chida
Journal:  Lung       Date:  2009-04-22       Impact factor: 2.584

Review 7.  Pneumomediastinum and subcutaneous emphysema secondary to amyopathic dermatomyositis with cryptogenic organizing pneumonia in invasive breast cancer: a case report and review of literature.

Authors:  Sung Hwan Park; Yoon-Seup Kum; Kyung-Chan Kim; Jung-Yoon Choe; Sung-Hoon Park; Seong-Kyu Kim
Journal:  Rheumatol Int       Date:  2008-12-18       Impact factor: 2.631

8.  Dermatomyositis with hemorrhagic myositis.

Authors:  Masashi Yamagishi; Shunji Tajima; Aki Suetake; Hidenori Kawakami; Takeo Watanabe; Hideyuki Kuriyama; Toshinori Takada; Eiichi Suzuki; Fumitake Gejyo
Journal:  Rheumatol Int       Date:  2008-12-17       Impact factor: 2.631

9.  Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease.

Authors:  Dong Jin Go; Jin Kyun Park; Eun Ha Kang; Hyun Mi Kwon; Yun Jong Lee; Yeong Wook Song; Eun Bong Lee
Journal:  Rheumatol Int       Date:  2015-07-30       Impact factor: 2.631

10.  Skin ulcer is a predictive and prognostic factor of acute or subacute interstitial lung disease in dermatomyositis.

Authors:  Kazuyoshi Ishigaki; Junko Maruyama; Noboru Hagino; Atsuko Murota; Yasunobu Takizawa; Ran Nakashima; Tsuneyo Mimori; Keigo Setoguchi
Journal:  Rheumatol Int       Date:  2013-04-04       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.